| Company/Division name | Bayer |
| Parent company | Bayer AG |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2022 |
| Offshore, work was done: | In-house |
| Capital investment ($): | 2200 |
| Country(ies) from which reshored: | Germany |
| City reshored to: | Berkeley |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | cell and gene therapies |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |
